Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
50 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Novalis II from Gent, company number BE0757877529, closed financial year 2025 with a result of € -575,322 after tax. For that financial year Novalis II recorded a gross margin of € -580,453 and equity of € 16.1 million. Compared with financial year 2024, the result moved from € -705,227 to € -575,322. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 26, 2026.
€ 16.1 million
▲ 44% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -575,322
▲ 18 % less loss than in 2024
Profit after tax over the fiscal year.
€ 2.5 million
▲ € 2.1 million vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -3 million.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 19,008
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -567,186 | € -566,158 | € -569,750 | € -580,453 | ▼ € 10,703 |
| Profit after taxes | € -567,419 | € -565,675 | € -705,227 | € -575,322 | ▲ € 129,906 |
| Equity | € 9,770,978 | € 9,205,302 | € 11,241,575 | € 16,149,253 | ▲ 44% |
| Total debts | € 152,128 | € 249,553 | € 38,000 | € 20,130 | ▼ 47% |
| Cash | € 5,323,943 | € 1,895,195 | € 366,480 | € 2,478,837 | ▲ € 2.1 million |
| Retained profit | € -1,195,022 | € -1,760,698 | € -2,465,925 | € -3,041,247 | ▼ € 575,322 |
| Balance sheet total | € 9,923,106 | € 9,454,855 | € 11,279,575 | € 16,169,383 | ▲ 43% |
Key figures of Novalis II, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Novalis II?
What happened at Novalis II in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 575,322. Source: NBB ↗
- New establishment in Gent. KBO
- NOVALIS II GENERAL PARTNER BV became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 567,419 loss in 2022 to € 575,322 loss in 2025.
A new publication or filing at Novalis II? We notify you, reason included.
Follow Novalis IIDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Participatiemaatschappij Vlaanderen, QUAESTOR BIOTECH comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Novalis IIBehind Novalis II is NOVALIS II GENERAL PARTNER BV. The shares are held by Participatiemaatschappij Vlaanderen (20.4%) and QUAESTOR BIOTECH (16.8%). It owns 85.1% of H42 Inc., 50% of pEGGY, 27.7% of RHEUMAFINDER, 18.2% of CARROUCELL, 17.6% of RHEAVITA and 14.8% of TRINCE BV itself.
Directors
According to the 2025 annual accounts
since 2020
Shareholders
Participations
H42 Inc.
85.1%
50%
27.7%
18.2%
17.6%
14.8%
ALITHEA GENOMICS SA
12.1%
Establishments
Establishment units
Physical locations of this company
Ottergemsesteenweg-Zuid 808 box 511
9000 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 50 companies are registered at this address.
All companies at this address →Schaeffler Belgium
€ 21.9 million revenue · 2025
KONINKLIJKE ATHLETIEK ASSOCIATIE GENT - Voetbalafdeling
€ 37.5 million revenue · 2025
Bontinck Architecture and Interior NV
€ 2.5 million revenue · 2026
Sales Management Association Belgium
KAAG Management
€ 136,551 gross margin · 2025
+45 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0757.877.529
- VAT number
- BE 0757.877.529
- Registered office
- Ottergemsesteenweg-Zuid 808 bus 511, 9000 Gent
- Names & denominations
- Novalis II
- Enterprise type
- Rechtspersoon
- Legal form
- Limited partnership
- Legal situation
- Normale toestand
- Start date
- 6 November 2020
- Peppol
- Active · Active since 19 Dec 2025
- Activities · NACE
Activiteiten van holdings
Holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige ondersteunende activiteiten in verband met financiële diensten, neg, exclusief verzekeringen en pensioenfondsen
Overige zakelijke dienstverlening, neg
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering